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Abstract. The present study sought to estimate the applicability
of apurinic/apyrimidinic endodeoxyribonuclease 1 (APE1),
vascular endothelial growth factor A (VEGFA) expression and
CD163+ tumor‑associated macrophage (TAM) ratio as prognostic factors in bladder cancer (BCa). A total of 127 patients
with bladder urothelial cancer who underwent radical cystectomy at Daping Hospital were recruited between January 2013
and January 2017, including 45 cases of non‑muscle invasive BCa (NMIBC) and 82 of MIBC. Immunohistochemical
detection of APE1, VEGFA and CD163, as well as multiple
immunofluorescence staining for APE1, VEGFA, CD163
and CD34, were performed on tissue samples. For APE1 and
VEGFA, the staining was graded based on intensity (0‑3),
while CD163 was graded (0‑3) based on the percentage of
positively stained cells. The prognostic value of APE1, VEGF
and CD163 was assessed using Kaplan‑Meier and Cox regression analysis. The results suggested that in BCa, high APE1
expression was associated with high VEGFA expression and
more infiltration of CD163+ TAM. Furthermore, high expression of APE1 was associated with lymphovascular invasion
of BCa, as well as reduced survival time. This indicates that
APE1 may be associated with CD163+ TAM infiltration in
BCa, with VEGFA as a possible influencing factor.
Introduction
Bladder cancer (BCa) is one of the most common types of
urological cancer, resulting in ~150,000 deaths worldwide
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every year (1). Approximately 75% of new BCa cases present
as non‑muscle‑invasive BCa (NMIBC) and up to 50% of them
will recur with 20% of these recurring cases progressing (2).
Treatment options for BCa vary based on the stage at diagnosis.
For MIBC and recurrent NMIBC, radical cystectomy (RC)
is usually the mainstay of treatment, where the goal is to
provide optimal cancer control by removal of whole bladder
tissue (3). Despite this, ~4‑10% of patients are still susceptible
to secondary urothelial tumors following RC and frequently
have an adverse prognosis due to late diagnosis (4). Although
numerous serum and urine biomarkers have been suggested,
their precision and specificity still require further evidence (5).
Therefore, identification of a novel molecular mechanism or
biomarker that may provide a novel treatment option, retard
the progression of Bca, improve the prediction of the prognosis
of BCa may provide a significant benefit in terms of benefiting
clinical treatment greatly.
Apurinic/apyrimidinic endodeoxyribonuclease 1 (APE1)
protein, also known as redox factor‑1 (Ref‑1), was originally
identified as a multifunctional protein involved in DNA base
excision repair (BER) and redox signaling. Previous studies
have indicated that APE1 expression is not only significantly
higher in multiple cancer types, including liver cancer, ovary
cancer and osteosarcoma, but also highly associated with
prognosis (6‑8). Although APE1 was suggested as a urinary
biomarker (5,9), its prognostic value in cancer tissue has not
been verified with sufficient cases.
Previously, Sun and Nelson (10) suggested that the
DNA repair gene APE1 is able to promote the production
of a spectrum of cytokines, growth factors and proteases,
including vascular endothelial growth factor (VEGF), by
the DNA damage secretory program. In the tumor microenvironment (TME), VEGF is secreted by tumor cells and
diffuse through the tissue contributing to angiogenesis (11).
Furthermore, VEGF has a role as an immunosuppressive
gene, inducing a ‘tumor endothelial barrier’ to promote T‑cell
arrest, or the loss of T cell motility (12). In BCa, VEGF has
been indicated to be associated with stage and recurrence.
Wheeler et al (13) suggested that VEGF is able to recruit
macrophages and polarize them to the M2 phenotype in the
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decidua. This may provide a novel mechanism to how VEGF
is able to worsen the clinical outcomes of BCa through
tumor‑associated macrophage (TAM) manipulation. The study
of TAMs impacting the progression and metastasis of cancer
has been fruitful. Alternatively activated M2 macrophages in
TME are responsible for angiogenesis and tissue remodeling
and feature an immunosuppressive phenotype, which may have
an important role in tumor progression (14). In BCa, M2 type
macrophages are usually associated with poor response to
BCG therapy and may significantly limit its efficacy (15). Of
note, in MIBC, TAMs mostly infiltrate into the tumor areas as
opposed to stroma‑tumor margins in NMIBC, which is associated with an unfavorable clinical outcome (16).
Therefore, the present study sought to evaluate the association among the expression of APE1 and vascular endothelial
growth factor A (VEGFA) and the infiltration of M2 macrophages, as detected via the M2 marker CD163, as well as their
prognostic significance in BCa. To the best of our knowledge,
the present study was the first to implicate APE1 as a key factor
in the DNA damage response with polarization of TAM, laying
a foundation for elucidating the mechanism of the recurrence
of BCa and exploring the efficacy of immunotherapy for this
neoplasm.
Materials and methods
Patients and data collection. A total of 167 patients with BCa
subjected to radical cystectomy at Daping Hospital between
January 2013 and January 2017 were recruited without any
restriction by age or sex. Data collection was closed by
May 2019. Those patients who did not have a reported event
of death at the time of closure were included for calculation
of the median follow‑up time. Patient follow‑up was usually
performed every 3 months in the first year post‑surgery and
then every 6 months. The cause of death was determined
by chart review from patients' medical records or from
the death certificate. The follow‑up time was 4‑78 months
and the median follow‑up time was 48 months. Cases with
non‑urothelial carcinoma types and patients who died of
causes not associated with cancer were excluded, and cases
without precise follow‑up were also excluded, resulting in
127 remaining cases. All subjects were from a Han Chinese
population and were subjected to radical cystectomy at
Daping Hospital (Chongqing, China) with the diagnosis
made based on pathology. The general characteristics of
the patients are summarized in Table SI. The median age
was 64.25 years (range, 39‑88 years). There were 45 cases
of NMIBC and 82 cases of MIBC. In total, 10 cases were
low‑grade carcinoma and 117 were high‑grade carcinoma,
and 36 of the latter were indicated to have lymphovascular
invasion (LVI). Regarding the smoking history, a person who
had at least one pack of cigarettes/day for >1 year in his/her
lifetime was regarded as having a positive smoking history;
otherwise, they were considered as a non‑smoker (17). The
study was approved by the Ethics Committee of Daping
Hospital (Chongqing, China).
Pathological evaluation and immunohistochemistry (IHC).
Tumor tissues were fixed overnight in 4% paraformaldehyde, dehydrated, embedded in paraffin and sectioned into

8‑10 mm (RM2235; Leica Microsystems). Experienced
pathologists blinded to the clinical outcomes reviewed these
pathological specimens. The tumors were staged according
to the 8th AJCC TNM staging classification (18). Grading
was performed following the 1998 WHO/ISUP consensus
classification (19). The presence of LVI was assessed in
all specimens. IHC staining for APE1, VEGFA and CD163
was conducted utilizing the following antibodies: APE1
(1:2,000 dilution; mouse monoclonal; cat. no. ab194; Abcam),
VEGFA (1:150 dilution; mouse monoclonal; cat. no. ab52917;
Abcam) and CD163 (1:150 dilution; mouse monoclonal; cat.
no. TA506388; Origene). Goat antibodies conjugated to horseradish peroxidase (HRP) (working solution, Kit‑5030; MXB)
was used as a secondary antibody, 3,3'‑diaminobenzidine
was used as a chromogenic substrate and the sections were
counterstained with hematoxylin. The results were analyzed
by an experienced pathologist (HX) blinded to the clinical
outcomes. APE1 and VEGFA expression were graded based on
the staining intensity of the nuclei and cytoplasm, respectively,
in the tumor area. Necrotic areas were ignored. Grade 0 had
the weakest staining and grade 3 had the strongest staining. In
the evaluation of APE1 expression, grade 0‑2 was considered
to indicate low expression, while grade 3 was considered to
indicate high expression. For VEGFA expression, grade 0‑1
was considered low expression, while grade 2‑3 was considered as high expression. For CD163, the percentage of stained
macrophages in the tumor stroma compared to the total
number of nucleated stromal cells was scored using a scale
from 0 to 100% and graded as follows: 0, 0‑5%; 1, 6‑30%;
2, 31‑50%; and 3, >50%. For evaluation purposes, grade 0‑1 is
considered as low TAM ratio, inversely grade 2‑3 is considered
as high ratio. The cutoff is set by mainly taking the median
grade value in consideration.
Multiple immunofluorescence staining. Multiple immunofluorescence staining was performed on paraffin‑embedded
tissues. Sections of 4 µm thickness were cut from selected BCa
tissues. The slides were deparaffinized in xylene, rehydrated
and washed with tap water prior to boiling in Tris‑EDTA buffer
(pH 9, 643901; Klinipath) for epitope retrieval/microwave treatment. Endogenous peroxidase was blocked using Antibody
Diluent/Block (cat. no. 72424205; Perkin Elmer) and incubated
at room temperature. Protein blocking was performed using
Antibody Diluent/Block at 37˚C for 1 h. The slides were incubated with primary antibodies to CD163 (1:150 dilution; cat.
no. ZM0428; Zsbio), APE1 (1:2,000 dilution; cat. no. ab194;
Abcam) and VEGFA (1:100 dilution; cat. no. ab52917; Abcam)
for 1 h at 37˚C, and then incubated with antibody to CD34
(cat. no. kit‑0004; MXB) at 4˚C overnight. Next, incubation
with Opal Polymer HRP Ms+Rb (cat. no. 2414515; Perkin
Elmer) was performed at 37˚C for 10 min. Tyramide signal
amplification (TSA) visualization was performed with the Opal
eight‑color IHC kit (cat. no. NEL797B001KT; Perkin Elmer),
containing fluorophores DAPI, Opal 690 (CD34), Opal 650
(VEGFA), Opal 570 (APE1) and Opal 520 (CD163), as well as a
TSA Coumarin system (cat. no. NEL703001KT; Perkin Elmer).
Slides were scanned using the Perkin Elmer Vectra
(Vectra 3.0.5; Perkin Elmer). Multispectral images were
unmixed using spectral libraries built from images of single
stained tissues for each reagent using the inform Advanced
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Figure 1. (A) Representative immunohistochemistry results for APE1, VEGFA and CD163 indicated that APE1 staining was mainly located in the nuclei and
partly in the cytoplasm and VEGFA was present in the cytoplasm of tumor cells, while CD163 was expressed on the infiltrating macrophages (magnification, x200). The staining was rated as 0, 1+, 2+ or 3+ based on intensity for APE1 and VEGFA and based on the percentage of positive cells for CD163.
(B) Heatmap presentation of the gradings of APE1, VEGFA and CD163 among the 127 patients. VEGFA, vascular endothelial growth factor A; APE1,
apurinic/apyrimidinic endodeoxyribonuclease 1.

Image Analysis software (inForm 2.3.0; Perkin Elmer). A selection of 5‑10 representative original multispectral images was
used to train the inForm software (tissue segmentation, cell
segmentation, phenotyping tool and positivity score). All the
settings applied to the training images were saved within an
algorithm to allow the inForm software (PerkinElmer; v2.3.0)
batch analysis of multiple original multispectral images of the
same tissue (20).
Statistical analysis. Data analysis was performed using SPSS
(version 22; IBM, Corp.) and GraphPad Prism 7 (GraphPad
Software, Inc.). Cumulative survival probabilities were
estimated using the Kaplan‑Meier method and differences
between survival rates were tested for significance using the
log‑rank test. Univariate and multivariate Cox regression
analyses were calculated using SPSS. Hazard ratios (HRs) and
95% confidence intervals (95% CI) were used to present the
associations of dependent and independent variables with the
risk of mortality. The χ2 test was employed to assess differences between two groups. All tests were two‑sided with
a 95% CI and P<0.05 was considered to indicate statistical
significance. Receiver operating characteristic (ROC) analysis
was conducted for further evidence. Correlation of APE1,
VEGFA and CD163 expression in muscle invasive bladder
cancer tissues with multiple immunofluorescence staining was
analyzed with Pearson correlation.

Results
Expression of APE1, VEGFA and CD163+ TAMs in BCa
tissues. IHC was used to estimate the expression of APE1
and VEGFA, as well as the ratio of CD163+ TAMs, and the
association between each of them with the clinicopathological
characteristics was determined. APE1 was mainly localized
in the nuclei with a certain amount residing in the cytoplasm,
whereas VEGFA appeared in the cytoplasm only (Fig. 1).
Among the 127 patients, 62 (48.82%) and 67 (52.76%) exhibited elevated levels of APE1 and VEGFA, respectively. The
APE1 levels appeared to be associated with LVI (P=0.019)
but not with the tumor stage or grade (Table SII). The levels
of VEGFA were not associated with the tumor stage, grade
or LVI. CD163+ TAMs were present in the tumor stroma
and tumor islets. The tumor stroma included the papillary
axis, lymphoid aggregates and the stroma. In certain specimens, staining for CD163 was positive in the cytoplasm and
membrane of tumor cells. Of the 127 cases, 62 (48.82%) had a
high grade regarding CD163+ TAMs but this was not associated with the tumor stage, grade or LVI.
APE1 and VEGFA expression is correlated with the CD163+
TAM ratio in BCa. The correlation between the expression of APE1 and VEGFA and the proportion of CD163+
M2 macrophages was then assessed. The results suggested
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Figure 2. Multiple immunofluorescence staining for APE1, VEGFA, CD163 and CD34 in bladder cancers. (A) Representative sample with high expression of
APE1 and VEGFA in which the intratumor CD163‑labeled M2 macrophages are easily distinguishable. (B) Example of a sample with high expression of APE1
and VEGFA in which the CD163‑labeled M2 macrophages are easily distinguishable in the tumor stroma. (C) Representative sample with low expression of APE1
and VEGFA, in which the CD163‑labeled M2 macrophages are less distinguishable. APE1‑positive staining in tumor epithelial cells displayed as orange and
VEGFA‑positive staining in tumor epithelial cells was cyan, while CD163‑positive infiltrating M2 macrophages were green and CD34‑positive vascular endothelial cells displayed as magenta (magnification, x200). VEGFA, vascular endothelial growth factor A; APE1, apurinic/apyrimidinic endodeoxyribonuclease 1.

that high expression of APE1 in tumor cells was positively
correlated with the grade regarding CD163+ TAMs (r=0.196,
P=0.027), as well as with VEGFA expression (r=0.208,
P=0.018). Furthermore, VEGFA expression was strongly
correlated with the grade regarding CD163+ TAMs (r=0.408,
P<0.001; Table SIII). To further assess the expression of APE1
and VEGFA in BCa tissues and their correlation with the
CD163+ TAM ratio, multiple immunofluorescence staining
for APE1, VEGFA, CD163 and CD34 was performed. The
results suggested that APE1 and VEGFA were co‑expressed
in tumor cells, and CD163+ TAMs were mostly distributed
around the microvasculature of tumor stroma or between
tumor cells (Fig. 2). Further analysis using inForm software
suggested that APE1 expression is positively correlated with
VEGFA and CD163 expression (Table SIV).
APE1 and CD163 are independent prognostic factors for
OS in BCa. KM analysis revealed that high APE1 expression and a high CD163+ TAM ratio were associated with a
shorter OS (Fig. 3). A univariate Cox regression analysis
for the expression of APE1, VEGFA, CD163+ TAMs and
clinical characteristics was performed, indicating that the
T‑stage (HR=8.279, 95% CI: 2.948‑23.255, P<0.001), N‑stage
(HR=4.265, 95% CI: 2.262‑8.045, P<0.001), LVI (HR=2.974,
95% CI: 1.642‑5.387, P<0.001), APE1 expression (HR=2.797,
95% CI: 1.486‑5.267, P=0.001) and CD163+ TAMs (HR=2.425,
95% CI: 1.300‑4.521, P=0.005) were associated with prognosis.
In addition, a multivariate analysis for OS was performed by
combining the marker panel and clinical variables, suggesting
that the T‑stage (HR=8.279, 95% CI: 2.948‑23.255, P<0.001),
N‑stage (HR=4.265, 95% CI: 2.262‑8.045, P<0.001), APE1
expression (HR=2.797, 95% CI: 1.486‑5.267, P=0.001) and
CD163+ TAMs (HR=2.425, 95% CI: 1.300‑4.521, P=0.005)

were independent prognostic factors (Table I). Area under the
curve are shown in Table SV.
Discussion
Multiple nomograms and models have been constructed in the
past to predict the outcomes of Bca (21). Accurate risk stratification may provide a marked benefit for patients with NMIBC that
qualify for early RC, as well as for patients with MIBC, who gain
from perioperative chemotherapy. The identification of new characteristics will substantially increase the fidelity of such models.
The presence of LVI, defined as the presence of tumor cells
in the lymphatic vessel and in vascular walls, has been reported
to be of prognostic value in patients with Bca. Evidence
suggests that LVI is a characteristic of biologically and clinically aggressive BCa and may be of prognostic value. In the
present study, 34 out of 127 patients were identified to have
LVI, 32 of which had MIBC and 2 had NMIBC (Table SII). In
addition, the presence of LVI is associated with an unfavorable
prognosis. This is consistent with other studies (22).
Aromatic amines are well‑known risk factors for BCa (23).
Interaction between environmental exposure and genetic
susceptibility may markedly increase DNA damage and thus
trigger urothelial precancerous events; therefore, prompt
elimination of such damage counteracts malignant transformation. The BER pathway has a critical role in DNA repair
mechanisms by removing nucleobase modifications by oxidation, alkylation and deamination, and also repairs backbone
single‑strand DNA breaks (24). The enzyme APE1 has a
mainframe role in BER by correcting apurinic/apyrimidinic
sites, which are pre‑mutagenic lesions able to stall DNA
replication forks. Studies have indicated above‑basal expression levels of APE1 and other DNA repair pathway proteins
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Table I. Univariate and multivariate COX analysis of the prognosis of IHC marker for OS.

Variable

Univariate
-------------------------------------------------------------------------------------------HR
95% CI
P-value

Agea
Sexb
Smokingc
LVId
T-stagee
N-stagef
Gradeg
APE1h
VEGFAi
CD163j

1.492
1.047
0.913
2.974
8.279
4.265
2.201
2.797
0.860
2.425

0.829-2.687
0.413-2.654
0.479-1.741
1.642-5.387
2.948-23.255
2.262-8.045
0.530-9.135
1.486-5.267
0.479-1.544
1.300-4.521

0.182
0.923
0.783
<0.001
<0.001
<0.001
0.277
0.001
0.613
0.005

Multivariate
--------------------------------------------------------------------------------------------HR
95% CI
P-value

12.857

3.883-42.575

<0.001

3.644
0.410
2.883

1.863-7.129
0.217-0.773
1.480-5.617

<0.001
0.006
0.002

Age, ≤65 vs. >65 years; bsex, male vs. female; csmoking: positve smoking history vs. negative smoking history; dLVI, lymphovasular invasion vs. no lymphovascular invasion; eT-stage, Tis and T1 vs. T2, T3 and T4; fN-stage, N0 vs. N1 and N2; ggrade, high grade vs. low grade;
h
APE1, high APE1 expression vs. low APE1 expression; iVEGFA, high VEGFA expression vs. low VEGFA expression; jCD163, high CD163
ratio vs. low CD163 ratio. Analysis were performed utilizing logistic regression using the Cox proportional hazards model on SPSS 17.0.
Area under the curve is shown in Table SV. HR, hazard ratio; VEGFA, vascular endothelial growth factor A; APE1, apurinic/apyrimidinic
endodeoxyribonuclease 1; LVI, lymphovascular invasion.
a

in high‑grade BCa (25). Choi et al (5) proposed that APE1
may be used as a non‑invasive urinary biomarker for BCa;
however, its sensitivity and specificity are not satisfying for
immediate clinical results. Recently, Fishel et al (26) reported
that APE1 was overexpressed in human BCa tissue and that
APE1 redox signaling‑specific inhibitor APX3330 was able
to attenuate the proliferation of BCa cells and increase their
apoptosis. However, the potential capability of APE1 expression levels to differentiate between NMIBC and MIBC has not
been previously reported. The present study suggested an even
distribution of APE1 expression in both NMIBC and MIBC,
with no significant difference between the two (P=0.711).
Furthermore, no significant difference in APE1 expression
was determined between high‑grade and low‑grade BCa
(P=0.744). However, high APE1 expression was associated
with the presence of LVI and unfavorable prognosis in patients
with BCa. APE1 expression was also positively correlated with
VEGFA and CD163+ TAM ratio in BCa tissue.
Previous studies have indicated that high expression of
APE1 in lung cancer and osteosarcoma is associated with
upregulated VEGF through hypoxia‑inducible factor‑1α activation and retardation of APE1 results in a significant drop
in VEGF expression (27). Of note, Pignot et al (28) analyzed
the angiogenic pathways in human transitional cell carcinoma
of the bladder using a large‑scale real‑time reverse transcription‑PCR approach, indicating that VEGFA, MET, C‑X‑C motif
chemokine receptor 4 and interleukin‑8 were significantly overexpressed in tumor samples, but only VEGFA overexpression
was an independent prognostic factor for overall and disease‑free
survival. This did not align with the present analysis of VEGFA
expression at the protein level, as no significant prognostic value
for VEGFA was determined in BCa; perhaps a further study
with more cases will better indicate the correlation between
transcriptional levels and protein expression of VEGFA in BCa.

VEGF and its receptors have profound effects on the early
development and differentiation of both vascular endothelial and
hematopoietic progenitors. Kloepper et al (29) further suggested
that when subjecting glioblastoma to anti‑VEGF/angiopoietin‑2
blockade, TAMs along the M1 to M2 continuum are being
reprogrammed toward the M1 phenotype to provide a greater
survival benefit. This suggested that VEGF may have a novel
role in immunosuppression by M2 polarization.
Macrophage infiltration is associated with significantly
better cancer‑specific survival in patients with CD163+
TAM‑associated tumors. A meta‑analysis of 1,400 cases of
BCa including 13 studies further indicated that only CD163+
TAMs, not CD68+ TAMs, were closely associated with OS,
recurrence‑free survival and progression‑free survival (30).
Consistent with the present results, macrophage infiltration
was indicated to be associated with the prognosis of BCa. The
present study demonstrated through IHC and multiple immunofluorescences staining that a high CD163+ macrophage ratio
is associated with an unfavorable prognosis.
Recently, Hudson et al (31) published a comparative study
of 19 glioma specimens with recurrence after treatment.
Through screening of 96 gene expressions, APE1 expression
in tumor tissues was significantly increased after treatment.
In addition, genes linked to immunosuppression, invasion and
metastasis (glycoprotein nmb, C‑C motif chemokine ligand 5
and killer cell lectin‑like receptor C1) and an M2 phenotype (CD163) were also detected. The polarized genes were
significantly upregulated. In 2018, Yan et al (32) reported that
the APE1‑specific redox inhibitor APX3330 directly affected
the polarization of M2 macrophages in the role of neurological
recovery after stroke in type I diabetic rats. However, the
specific mechanism by which APE1 regulates M2 polarization
has remained elusive. The present results confirmed a positive
correlation between APE1, VEGFA and CD163 at the protein
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contributing factor due to its association with other meaningful
factors, including APE1 and CD163 expression. Further studies
on this mechanism will be required to draw a conclusion.
The present study demonstrated that high APE1 expression
is associated with the presence of LVI in BCa. APE1 expression
was also determined to be positively associated with VEGFA
expression and increased infiltration of CD163+ TAM. LVI,
high APE1 expression and a high ratio of CD163+ TAM in BCa
may lead to a reduced survival time of patients. The results
may add valuable insight to optimize models predicting BCa
prognosis, consequently guiding perioperative treatments that
benefit patients the most. The present study also indicated that
there may be a mechanism by which high APE1 expression
contributes to an increase of M2‑type TAMs by definition as
CD163+, possibly involving regulation of VEGFA expression
through its redox function. However, the present results are
limited in that only patients subjected to radical cystectomy
were recruited, and studies including patients with broader
recruitment criteria (not only restricting to patients who underwent cystectomy but, for example, also those who underwent
transurethral resection) will provide a better analysis. In addition, only paraffin‑embedded tissues were assessed and there
was a lack of fresh tissues, which may limit the conclusions of
the present study. Further prospective studies with standardized protocols should be performed to fully assess the impact
of LVI, APE1 and VEGFA expression, as well as the CD163+
TAM ratio, on the outcomes for patients with BCa.
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